Veracyte, Inc. revenue by segment VCYT

Annual Quarterly

Veracyte, Inc. splits its revenue into 5 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Testing at $146.4 million, 96% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Revenue	582	152	150	139	141	132	130	114	119
Testing	563 +19.9% share 96.8%	146 +14.6% share 96.5%	146 +19.1% share 96.9%	135 +25.9% share 97.1%	136 +21.1% share 96.6%	128 share 96.9%	122 share 93.9%	107 share 93.7%	112 share 94.5%
Product	16 +18.6% share 2.8%	5 +40.1% share 3.0%	4 share 2.6%	4 +2.8% share 2.6%	4 +27.5% share 2.7%	3 share 2.5%	—	4 share 3.1%	3 share 2.5%
Testing Other	14 +147.3% share 2.3%	2 +60.0% share 1.6%	—	—	2 +38.9% share 1.8%	2 share 1.1%	2 share 1.4%	0 share 0.3%	2 share 1.5%
Biopharmaceutical And Other	3 -77.2% share 0.5%	1 -13.0% share 0.5%	1 -81.4% share 0.5%	0 -91.6% share 0.2%	1 -72.2% share 0.7%	1 share 0.6%	4 share 3.3%	4 share 3.1%	3 share 2.9%
Biopharmaceutical And Other Contract Manufacturing And Testing	—	—	—	—	-0 -100.0% share -0.0%	0 share 0.1%	2 share 1.3%	1 share 1.1%	2 share 1.9%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Services-Medical Laboratories (SIC 8071)
Listed as: VCYT (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: South San Francisco, CA
SEC filer status: Large accelerated filer
SEC CIK: 1384101
Former names: CALDEROME INC (until Feb 27, 2008)

Other Services-Medical Laboratories companies

All 29 Services-Medical Laboratories companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.